PRADA: Do Cardioprotective Drugs During Adjuvant Therapy For Breast Cancer Improve CV Outcomes?

Published by W Butcher on

Cardioprotective drugs during adjuvant therapy for early-stage breast cancer do not protect against long-term decline in cardiac function, according to new data from the PRADA trial presented May 16 during ACC.21 and simultaneously published in Circulation. In the single center, double-blind trial, Siri Lagethon Heck, MD, PhD, et al., assessed the long-term impact of candesartan cilexetil (32 mg), metoprolol succinate (100 mg), a combination, or a placebo on preventing a decrease in cardiac function and myocardial injury. Using a 2×2 factorial design, 120 patients with early-stage breast cancer receiving anthracycline-containing chemotherapy after surgery were randomized 1:1:1:1 to the four treatment arms. Cardiac MRI was performed at the start of the study and after a median of 23 months.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.